The effects of Aspergillus fumigatus challenge on exhaled and nasal NO levels

European Respiratory Journal

Volumn 26, Issue 5, 2005, Pages 887-893

  Stark, Harri J ^a   Randell, J T ^a   Hirvonen, M R ^b   Purokivi, M K ^a   Roponen, M H ^b   Tukiainen, H O ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Acute mould challenge; Aspergillus fumigatus; Exhaled nitric oxide; Nasal nitric oxide

Indexed keywords

NITRIC OXIDE; NITRITE; PLACEBO;

ADULT; ARTICLE; ASPERGILLUS FUMIGATUS; ATOPY; CLINICAL ARTICLE; CONTROLLED STUDY; EXHALATION; FREQUENCY ANALYSIS; HUMAN; INHALATION; LAVAGE; LUNG FUNCTION; MOULD; NONHUMAN; NOSE CAVITY; NOSE MUCUS; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; SYMPTOMATOLOGY;

ADULT; ASPERGILLUS FUMIGATUS; BIOLOGICAL MARKERS; BREATH TESTS; EXHALATION; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS;

EID: 27744518832     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00061405     Document Type: Article

References (35)

1. Bornehag CG, Blomquist G, Gyntelberg F, et al. Dampness in buildings and health. Nordic interdisciplinary review of the scientific evidence on associations between exposure to "dampness" in buildings and health effects (NORDDAMP). Indoor Air 2001; 11: 72-86.
2. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133-135.
3. Martin U, Bryden K, Devoy M, Howarth P. Increased levels of nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. J Allergy Clin Immunol 1996; 97: 768-772.
4. Hirvonen MR, Ruotsalainen M, Roponen M, et al. Nitric oxide and proinflammatory cytokines in nasal lavage fluid associated with symptoms and exposure to moldy building microbes. Am J Respir Crit Care Med 1999; 160: 1943-1946.
5. Roponen M, Kiviranta J, Seuri M, Tukiainen H, Myllykangas-Luosujärvi R, Hirvonen M-R. Inflammatory mediators in nasal lavage, induced sputum and serum of employees with rheumatic and respiratory disorders. Eur Respir J 2001; 18: 542-548.
6. Purokivi M, Hirvonen M-R, Randell J, Roponen M, Tukiainen H. Nitric oxide alone is insufficient biomarker of exposure to microbes in a moisture-damaged building. Inhal Toxicol 2002; 14: 1279-1290.
7. Meklin T, Husman T, Vepsäläinen A, et al. Indoor air microbes and respiratory symptoms of children in moisture-damaged and reference schools. Indoor Air 2002; 12: 175-183.
8. Huttunen K, Ruotsalainen M, Iivanainen E, Torkko P, Katila M, Hirvonen M. Inflammatory responses in RAW264.7 macrophages caused by mycobacteria isolated from moldy houses. Environ Toxicol Pharmacol 2000; 8: 237-244.
9. Hirvonen MR, Suutari M, Lignell U, Nevalainen A. Effect of growth medium on potential of Streptomyces anulatus spores to induce inflammatory responses and cytotoxicity in RAW264.7 macrophages. Inhalation Toxicol 2001; 13: 55-68.
10. Hendry KM, Cole EC. A review of mycotoxins in indoor air. J Toxicol Environ Health 1993; 38: 183-198.
11. Samson RA, Flannigan B, Flannigan ME, Verhoeff AP, Adan OCC, Hoekstra ES. Health implications of fungi in indoor environments. In: Samson RA, Flannigan B, Flannigan ME, et al., eds. Air Quality Monographs. Vol. 2. Amsterdam, Elsevier Science BV, 1994; pp. 531-538.
12. Hyvärinen A, Reiman T, Meklin T, Husman T, Vahteristo M, Nevalainen A. Fungal exposure and IgG-levels of occupants in houses with and without mold problems. In: Johanning E, ed. Bioaerosols, Fungi and Mycotoxins: Health Effects, Assessment, Prevention and Control. Albany, NY, USA, Eastern New York Occupational and Environmental Health Center, 1999; pp. 166-168.
13. Tomee JF, van der Werf TS. Pulmonary aspergillosis. Neth J Med 2001; 59: 244-258.
14. Fischer G, Muller T, Schwalbe R, Ostrowski R, Dott W. Species-specific profiles of mycotoxins produced in cultures and associated with conidia of airborne fungi derived from biowaste. Int J Hyg Environ Health 2000; 203: 105-116.
15. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
16. Recommendations for DLCO. American Thoracic Society. Am J Respir Crit Care Med 1996; 154: 263.
17. Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking healthy adults. Scand J Clin Lab Invest 1982; 159: 5-20.
18. Purokivi M, Randell J, Hirvonen MR, Tukiainen H. Reproducibility of measurements of exhaled NO, and cell count and cytokine concentrations in induced sputum. Eur Respir J 2000; 16: 242-246.
19. Silkoff FE, Chatkin J, Qian W, et al. Nasal nitric oxide: a comparison of measurement techniques. Am J Rhinol 1999; 13: 169-178.
20. Graham DE, Koren HS. Biomarkers of inflammation in ozone exposed humans: comparison of the nasal and bronchoalveolar lavage. Am Rev Respir Dis 1990; 142: 152-156.
21. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Annal Biochem 1982; 126: 131-138.
22. Gross NT, Nessa K, Camner P, Jarststrand C. Production of nitric oxide by rat alveolar macrophages stimulated by Cryptococcus neoformans or Aspergillus fumigatus. Med Mycol 1999; 37: 151-157.
23. Ricciardolo FLM. Multiple roles of nitric oxide in the airways. Thorax 2003; 58: 175-182.
24. Purokivi M, Hirvonen M-R, Randell J, et al. Changes in proinflammatory cytokines in association with exposure to moisture-damaged building microbes. Eur Respir J 2001; 18: 951-958.
25. Paredi P, Leckie MJ, Horvath I, Allegra L, Kharitonov SA, Barnes PJ. Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma. Eur Respir J 1999; 13: 48-52.
26. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir J 1997; 10: 1683-1693.
27. Piipari R, Piirila P, Keskinen H, Tuppurainen M, Sovijarvi A, Nordman H. Exhaled nitric oxide in specific challenge tests to assess occupational asthma. Eur Respir J 2002; 20: 1532-1537.
28. Palm JP, Graf P, Lundberg JO, Alving K. Characterization of exhaled nitric oxide: introducing a new reproducible method for nasal nitric oxide measurements. Eur Respir J 2000; 16: 236-241.
29. Lundberg JO, Weitzberg E. Nasal nitric oxide in man. Thorax 1999; 54: 947-952.
30. Heldal KK, Halstensen AS, Thorn J, Eduard W, Halstensen TS. Airway inflammation in waste handlers exposed to bioaerosols assessed by induced sputum. Eur Respir J 2003; 21: 641-645.
31. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002; 325: 411-414.
32. Immonen J, Laitinen S, Taskinen T, Nevalainen A, Korppi M. Mould-specific immunoglobulin E antibodies in primary school students: a 3-year follow-up-study. Pediatr Allergy Immunol 2000; 14: 101-108.
33. Malling H-J. Diagnosis of mold allergy. Clin Rev Allergy 1992; 10: 213-236.
34. Persson M, Zetterström O, Agrenius V, Ihre E, Gustafsson L. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343: 146-147.
35. Robbins R, Millatmal T, Lassi K, Rennard S, Daughton D. Smoking cessation is associated with an increase in exhaled nitric oxide. Chest 1997; 112: 313-318.